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Abstract 
Duramycin, through binding with phosphatidylethanolamine, has been shown to be a selective 
molecular probe for the targeting and imaging of cancer cells. Photodynamic therapy aims to bring 
about specific cytotoxic damage to tumours through delivery of a photosensitising agent and light 
irradiation. Conjugation to biological molecules that specifically target cancer has been shown to 
increase photosensitiser selectivity and decrease damage to surrounding normal tissue. Duramycin was 
conjugated to a porphyrin based photosensitiser via direct reaction to the ε-amino group on the lysine 
residue near duramycin’s N-terminal and subsequently purified using RP-HPLC. Binding of the conjugate 
to ovarian and pancreatic cancer cell lines was assessed by flow cytometry. Light irradiation with a light 
fluence of 7.5 J/cm2 was delivered to conjugate treated cancer cells and cell survival analysed by MTT 
assay. The conjugate detected phosphatidylethanolamine on all 4 cancer cell lines in a concentration 
dependent manner and conjugate plus irradiation effectively reduced cell survival at concentrations 
>2.5 µM. Reduction in cell survival by conjugate plus irradiation was significantly enhanced, when
compared to unconjugated duramycin in A2780, AsPC-1 and SK-OV-3 cancer cells. In this study we have
shown that a duramycin-porphyrin conjugate retained good binding affinity for its target and, following
irradiation, reduced cell survival of pancreatic and ovarian cancer cell lines.
Keywords 
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1. Introduction 
Duramycin is a small tetracyclic peptide produced by the bacterium Streptoverticillium cinnamoneus [1]. 
Only 19 amino acids in length duramycin is one of very few identified, relatively, short peptides to have 
a defined 3-dimensional structure [2]. This structure is stable due to the presence of 4 intramolecular 
covalent bridges formed via the amino acids lanthionine, methyllanthionine, lysinoalanine and beta-
hydroxyaspartic acid [3]. This strength in structure may explain duramycin’s resistance to thermal and 
proteolytic degradation [2]. Three internal covalent bridges stabilise duramycin’s binding site which 
selectively recognises the ethanolamine head-group of the membrane phospholipid 
phosphatidylethanolamine (PE) [4]. Duramycin binds to PE with high specificity with a binding molar 
ratio of 1:1 [5]. PE is an abundant membrane phospholipid which is ubiquitous in eukaryotic cells. In 
quiescent cells PE is predominantly located on the inner cell membrane along with phosphatidylserine 
[6, 7]. The asymmetrical distribution of PE and phosphatidylserine is enzymatically maintained by a 
group of ATP dependent aminophospholipid translocases [8, 9]. On activation PE can become exposed 
on the outer cell membrane during a number of physiologically important processes such as apoptotic 
and necrotic cell death, reorganisation of the membrane during cytokinesis and initiation of the 
coagulation cascade [10-13]. Upregulation of cell surface PE expression has been observed in cancer 
cells, cancer derived microparticles and on the tumour endothelium of a variety of in vitro and in vivo 
tumours [1, 14-16]. 
Photodynamic therapy (PDT) is a minimally invasive treatment that can deliver selective cytotoxic 
activity towards cancer [17]. PDT requires three essential components; a photosensitising agent, light 
and oxygen. Accumulation of the photosensitiser (PS) at the site of cancer and activation with light at a 
specific wavelength causes the PS to transfer energy, via its excited triplet state, to molecular oxygen 
which is converted from its ground triplet state to an excited singlet state. This leads to the generation 
of cell damaging reactive oxygen species (ROS) which ultimately causes apoptotic or necrotic cell death 
[17, 18]. As well as its direct cytotoxic effect on cancer, PDT can have anti-tumour effects via induction 
of the inflammatory response and damage to tumour vasculature [19, 20]. PDT has been approved for 
treatment of a variety of cancer types including premalignant and malignant skin cancers [21, 22], early 
carcinomas of the oral cavity, pharynx, and larynx [23], cancers of the GI tract [24], prostate cancer, 
bladder cancer, non-small cell lung cancer and brain tumours [17]. A number of PS have been approved 
for use in clinical oncology including m-THCP (meta-tetrahydroxyphenylchlorin, Foscan®), ALA (5-
aminolevulinic acid, Levulan®) and its methyl ester (Metvix®) and porfimer sodium (Photofrin®). There are 
a wide range of PS still in pre-clinical and clinical trials [25, 26]. 
Porphyrins are highly conjugated heterocyclic tetrapyrroles that were first identified as having 
photodynamic properties in the 1970s [27, 28]. A porphyrin PS (5-[Aminobutyl-N-
oxycarbonyl)phenyl]phenyl]-10,15,20-tris(N-methyl-4-pyridinium) porphyrin trichloride) plus light 
irradiation was able to reduce cell survival and prevent colony forming in prostate epithelial cells at 
concentrations of >8.75 µM [29]. The porphyrins TTP (5,10,15,20-tetra-p-tolyl porphyrin) and THNP 
(5,10,15,20-tetra-p-naphthyl-porphyrin) after a light irradiation dose of 4.5 J/cm2 were able to cause cell 
death in a human melanoma cell line in a concentration dependent manner [26]. The main disadvantage 
of PDT is the low selectivity of PS to their target, which can lead to damage to surrounding normal tissue 
and sustained skin photosensitivity [17]. In an attempt to overcome this research in PDT in oncology has 
focused on developing PS’s conjugated to tumour targeted biological molecules [20]. Porphyrins have 
been successfully conjugated to a variety of biomolecules including mAbs [18, 30, 31], lipoproteins [32, 
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Duramycin-porphyrin conjugates for PDT 
4 
 
33] and nanoparticles [34] which allowed for more targeted delivery of PS, and therefore a more specific 
tissue response with limited damage to normal tissue. A number of porphyrins have been developed 
that conjugate to biomolecules under mild conditions through direct reaction with lysine residues [18, 
35, 36]. 
The two primary amines, cysteine and lysine, at the N-terminal of duramycin offer potential sites for 
conjugation without interference with duramycin’s binding site [3]. Using this theory a number of 
duramycin conjugates have been developed to take advantage of PE as a possible selective molecular 
probe. Fluorescent duramycin conjugates have been used to successfully target and image the 
lymphoma cancer cell line U937 [4], cancer derived microparticles [16], prostate tumour endothelium in 
rats [1] and the endothelium of aortic flow dividers [37]. Duramycin has been radiolabelled with 
gadolinium [3] and technetium-99m where it was used to image cell death in a rat model of acute 
myocardial infarction [38]. In this proof of concept study we conjugated duramycin to a porphyrin based 
photosensitiser and assessed its ability to bind to cancer cell surface PE. We also examined its cytotoxic 
activity on ovarian and pancreatic cancer cell lines following irradiation with visible light. 
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2. Materials and Methods 
2.1 Cell Culture  
The cancer cell lines AsPC-1 and MIA PaCa-2 were purchased from the American Type Culture Collection 
(UK). The cancer cell lines A2780 and SK-OV-3 were purchased from the European Collection of Cell 
Cultures (UK). All cells were grown using distributors’ instructions. All cells were cultured in either 
IMDM, McCoy’s 5a Medium Modified or RPMI (Lonza, UK) substituted with 10% FBS (15% for McCoy’s 
5a Medium Modified) (Bio-Sera, UK) and (v/v); 100 units/mL penicillin, 100 µg/mL streptomycin (P/S) 
(Lonza, UK). All serum was filtered using a 0.2 µM syringe filter prior to addition to media. When not in 
use all media was stored between 4-6 °C. All cells were incubated at 37 °C in a 5% CO2 atmosphere. Cells 
were cultured in tissue culture flasks (Sarstedt, UK) and removed via scraping when cells were 70-90% 
confluent.  
2.2 Conjugation of Porphyrin to Duramycin  
A solution of duramycin (Sigma-Aldrich, UK, 10 mg, 4.97x10-3 mmol) in DMSO (2 mL) plus trimethylamine 
was treated with 5-[4-(N-succinimidyloxycarbonyl)phenyl]-10,15,20-tris(4-methylpyridinium)porphyrin 
trichloride [39] (8 mg, 9.94x10-3 mmol) and the resulting solution was mixed on a rotating shaker at 
room temperature for 24 hours. The crude material was recovered by addition of dichloromethane (5 
mL) and filtration through paper. The solid was dissolved in 1 mL of 0.1% aqueous trifluoroacetic acid 
(TFA) and the 1:1 porphyrin/duramycin conjugate was isolated by semi-preparative HPLC and analysed 
by electron ionising mass spectrometry (ESI-MS) (section 2.3). Recovery of 4.8 mg of conjugate was 
achieved equating to 34.4% yield. An unconjugated, “capped” porphyrin was used as a control in which 
the NHS ester group used for conjugation was reacted with butylamine to eliminate any non-specific 
conjugation [29]. All photosensitiser containing compounds were kept, protected from light, at -20°C. 
Final concentrations of the re-suspended lyophilised powder of the conjugate and “capped” control 
were determined using UV-visible spectrophotometry. 
2.3 Analyses and Purification of Duramycin-Porphyrin Conjugate  
RP-HPLC-PDA analyses were performed on an Agilent 1200 HPLC system (Agilent, Germany) equipped 
with a G1312B BinPump SL, G13798 degasser, G1367D HiP ALS SL plus autosampler, a G1316B column 
compartment (set at 35 °C), and a G1315C diode array detector (acquisition rate, 80Hz; scan rate: 380-
600 nm, step: 1 nm), using a Gemini C18 column, 5 µ, 150 x 4.6 mm, 110 Å column (Phenomenex, UK), 
equipped with a SecurityGuard C18 (ODS) 4 x 3.0 mm ID guard column (Phenomenex, UK). The injection 
volume was 20 μL, and the flow rate was 1 mL/min. Mobile phase consisted of a mixture of 0.1% TFA in 
deionised water (18.2 MΩ, Elga Purelab Ultra ULXXXGEM2), solvent A, and 0.1% TFA in HPLC-grade 
acetonitrile, solvent B. The gradient for the elution was as follows: 0-2 min, 5% B; 2-7 min, B to 95%; 7-
12 min, 95% B; 12-12.1 min, B to 5%. Duramycin Rt = 7.32, porphyrin Rt = 7.01, conjugate Rt = 6.20 min 
(See supplementary figure S-1). RP-HPLC purifications were carried out on a Jasco HPLC system  
equipped with a PU-1580 LC pumps, HG-1580 degasser, AS-1555 autosampler and MD-1515 array UV-
visible detector, using a Luna C18, 5 µ, 250 x 10 mm, 110 Å (Phenomenex, UK), at a flow rate of 2.5 
mL/min. Mobile phase consisted of a mixture of 0.1% TFA in deionised water (18.2 MΩ, Elga Purelab 
Ultra ULXXXGEM2), solvent A, and 0.1% TFA in HPLC-grade acetonitrile, solvent B. The gradient for the 
elution was as follows: 0-8.5 min, 5% to 51% B; 8.5-13 min, 51% B; 13-14 min, 51 to 95% B; 14-18 min, 
95% B, 18-18.1 min, 95 to 5% B. Conjugate Rt = 6.20 min (See supplementary figure S-1). Q-TOF-MS data 
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were acquired in positive mode scanning from 400 to 3000 m/z with and without auto MS/MS 
fragmentation. Ionisation was achieved with an Agilent JetStream electrospray source and infused 
internal reference masses. Agilent 6540 Q-TOF-MS parameters: gas temperature, 325 °C; drying gas, 10 
L/min; and sheath gas temperature, 400 °C. ESI-MS (+): 675.66 [(M+4H+)/4]4+ (exp: 675.67). Conjugate Rt 
= 7.34 (see supplementary figure S-2). 
2.4 Flow Cytometric Detection of Phosphatidylethanolamine  
Cells (1 x 105) were re-suspended in 25 µl PBS and added to a 5mL polypropylene tube (Sarstedt, UK). 
Duramycin-porphyrin conjugate (5 µl) at required concentration was added to the tubes and incubated 
at room temperature in the dark for 30 minutes. Cells were washed with PBS, centrifuged at 320g for 3 
minutes and re-suspended in 300 µl PBS and then analysed using a BD FACScalibur (BD Biosciences, UK). 
2.5 Flow Cytometric Analysis of Forward Scatter and Side Scatter  
Analysis of forward scatter (FSC) and side scatter (SSC) data was performed using BD CellQuest Pro 
software™ version 5.1 (BD Biosciences, UK) after cells were processed using the method described 
above. FSC and SSC data using the unconjugated duramycin was collected as part of a study to 
determine the effect of duramycin on cell viability over a 2 hour time course (unpublished data). These 
cells were processed using a flow cytometric cell viability analysis method described previously [15]. 
Briefly cells (2 x 105) were incubated with an appropriate concentration of unconjugated duramycin at 
room temperature in the dark for 30 minutes and analysed using Annexin V: FITC Apoptosis Detection 
Kit I (BD Biosciences, UK). 
2.6 Competition Binding Assays  
Cells (2 x 105) were re-suspended in 40 µl PBS and added to a 5 mL polypropylene tube (Sarstedt, UK). 
Duramycin-porphyrin conjugate (10 µl, final concentration 50 µM) was added to the tubes and 
incubated at room temperature in the dark for 5 minutes. The cells were washed with PBS, centrifuged 
at 320g for 3 minutes and re-suspended in 40 µl PBS except for the 0 minute tube which was re-
suspended with 300 µl PBS and analysed by flow cytometry. Unconjugated duramycin (10 µl, final 
concentration 50 µM) was added to the remaining tubes. After appropriate incubation time (2, 5, 15 or 
30 minutes) 250 µl PBS was added to the tubes and the cells analysed using flow cytometry. 
2.7 Photodynamic Light Treatment Cells  
(8 x 105) in serum free medium were added to 5 mL polypropylene tubes (Sarstedt, UK) containing 
duramycin-porphyrin conjugate at required concentration (0-10 µM) and incubated in the dark at 37 °C 
in a 5% CO2 atmosphere for 5 minutes. Cells were then washed with 3 mL medium so as to remove any 
unbound conjugate and centrifuged at 300g for 10 minutes and re-suspended in 1 mL medium. Cells (8 x 
104) were then plated into 96 well plates and incubated in the dark at 37 °C in a 5% CO2 atmosphere for 
5 minutes. The PDT light supply (9x14 LED Array, wavelength 620-660 nm) was allowed to stabilise and 
irradiance reading taken using a R203 Macam radiometer (Irradian Ltd. UK). After incubation one plate 
was irradiated with a light fluence of 7.5 J/cm2 red light while the other served as the dark control (i.e. 
not irradiated). After light treatment 5 µl FBS was added to each well and the plates incubated at 37  °C 
in a 5% CO2 atmosphere for 24 hours. 
2.8 Cell Proliferation Assay  
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After 24 hours incubation 10 µl MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide; 
thiazolyl blue) (Sigma-Aldrich, UK) (12 mM solution in PBS) was added to each well of the 96 well plates. 
The plates were incubated at 37 °C in a 5% CO2 atmosphere for 4 hours and then the crystals were 
dissolved by adding 150 μl of acid‐alcohol mixture (0.04 mol/L HCl in absolute 2‐propanol). The plates 
were then analysed at 570 nm using a Biotek ELX800 Universal Microplate Reader (Corgenix Ltd., UK). 
Percentage cell survival was expressed relative to control values. 
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3. Results 
3.1 Phosphatidylethanolamine Detection  
The duramycin-porphyrin conjugate (Figure 1) was able to detect cell surface PE expression on the 
ovarian cancer cell lines, A2780 and SK-OV-3, and the pancreatic cancer cell lines, AsPC-1 and MIA PaCa-
2 using flow cytometry. Log10 median PE fluorescence (635 nm laser, FL-4 flow cytometer channel) was 
used to express levels of detected PE. The duramycin-porphyrin conjugate detected levels of PE in a 
concentration dependent manner on all 4 cell lines (Figure 2). Optimal PE detection was seen using 1 
mM conjugate. As an average of all 4 cell lines the log10 median PE fluorescence increased from 
0.17±0.007 when detected with 1 µM conjugate to 2.21±0.192 when detected with 1 mM conjugate. 
The duramycin-porphyrin conjugate was detectable through the flow cytometer’s FL-1 channel (flow 
cytometer’s 488 nm laser) due to fluorescence of the porphyrin component of the conjugate at this 
wavelength. 
3.2 Competitive Binding for Phosphatidylethanolamine  
To investigate whether the binding ability of the duramycin-porphyrin conjugate to PE was affected by 
the conjugation procedure a competition assay was performed using flow cytometry. The unconjugated 
duramycin was unable to compete for cell surface PE on the cancer cell lines which had been pre-
incubated with duramycin-porphyrin conjugate (Figure 3). The median PE fluorescence (FL-4 channel) of 
A2780 and MIA PaCa-2 was determined, using the pre-bound conjugate, as 10.9±0.75 and 16.7±5.9, 
respectively. Duramycin was incubated with the cancer cell lines for 0, 2, 5, 15 and 30 minutes to allow 
time to potentially displace the conjugate and competitively bind to PE. The median PE fluorescence of 
MIA PaCa-2 remained constant, within standard deviation, at each interval across the 30 minute time 
course. The median PE fluorescence of the A2780 however increased over time to the maximum of 
12.8±0.16 at 30 minutes. The unaffected binding affinity of the conjugate for PE after ligation to 
porphyrin provides evidence that the conjugation method used in this study does not disrupt PE binding. 
Alternatively, the assay was performed with the unconjugated duramycin pre-bound and the conjugate 
as the competing species, similarly over a 30 minute time course. The median PE fluorescence (FL-1 
channel) detected remained constant at 8.3±1.8 for A2780 and 11.7±1.4 for MIA PaCa-2 over the 30 
minutes. However it cannot be certain that the FL-1 signal originated from the unconjugated duramycin 
(labelled with a tertiary FITC antibody detected at 488 nm) as the duramycin-porphyrin conjugate signal 
is also detectable on this channel. 
3.3 Effect on Cell Size and Morphology  
We have previously reported the effect that unconjugated duramycin has on the morphology of A2780, 
AsPC-1, MIA PaCa-2 and SK-OV-3 with relation to an increase in cell size (FSC) and internal cell 
complexity/ granularity (SSC) [15]. FSC and SSC data collected via flow cytometry was analysed after the 
same 4 cancer cell lines were treated with the duramycin-porphyrin conjugate at concentrations 
between 1 µM and 1 mM (Figure 4). A2780 and SK-OV-3 increased in SSC when treated with 1 mM 
conjugate and AsPC-1 and MIA PaCa-2 increased in SSC when treated with >250 µM. A2780 and MIA 
PaCa-2 showed a slight increase in FSC when treated with 1 mM duramycin-porphyrin conjugate. 
3.4 Photodynamic Cytotoxicity Assays  
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The duramycin-porphyrin conjugate was used in the photodynamic treatment of the cancer cell lines 
A2780, AsPC-1, MIA PaCa-2 and SK-OV-3. The irradiated duramycin-porphyrin conjugate was able to 
reduce the cell survival of the A2780 cancer cells at concentrations >2.5 µM (Figure 5a). A significant 
difference in reduction in cell survival between the irradiated and non-irradiated conjugate treated cells 
occurred at 2.5 µM where cell survival was 53.7 and 74.4%, respectively. The conjugate at the highest 
concentration of 10 µM was able to reduce cell survival to 3.2%. The unconjugated duramycin caused a 
slight reduction in cell survival at concentrations >5 µM. The non-irradiated “capped” control porphyrin 
(porphyrin with no duramycin) showed no cytotoxicity. The irradiated “capped” control porphyrin 
however showed similar levels of cytotoxicity as the irradiated conjugate treated cells at concentrations 
>5 µM. MIA PaCa-2 cells showed less sensitivity to photodynamic light treatment than A2780. For 
conjugate treated MIA PaCa-2 cells the significant difference in reduction of cell survival between the 
irradiated and non-irradiated conditions occurred at 5 µM (Figure 5b). At 10 µM cell survival was 
reduced to 36.3%. The non-irradiated conjugate and “capped” control porphyrin showed no cytotoxicity. 
The irradiated “capped” control porphyrin reduced cell survival slightly at the highest concentration of 
10 µM. Reduction in cell survival of MIA PaCa-2 in conjugate treated cells was not significantly different 
to unconjugated duramycin treated cells. At a concentration of 10 µM the cell survival for the irradiated 
and non-irradiated unconjugated duramycin was 40.3% and 43.5%, respectively. The reaction to 
photodynamic light treatment was similar in the cancer cell lines AsPC-1 (Figure 5c) and SK-OV-3 (Figure 
5d). Both of these cell lines showed a slight reduction in cell survival when treated with 1.25 µM 
irradiated conjugate and a significant reduction at concentrations >2.5 µM. The cell survival of non-
irradiated AsPC-1 cells treated with 2.5 µM conjugate was 83.4% compared to irradiated cells at 6.3%. 
For SK-OV-3 cell survival was 91.2% and 11.7% for the non-irradiated and irradiated conditions, 
respectively. At the highest concentration of 10 µM duramycin-porphyrin conjugate reduced cell survival 
to 1.83% in AsPC-1 and 2.76% in SK-OV-3. The non-irradiated conjugate showed dark toxicity at 
concentrations >5 µM and the irradiated “capped” control porphyrin control slightly reduced cell 
survival at 10 µM for both cancer cell lines. Unconjugated duramycin showed a cytotoxic effect in a 
concentration dependent manner for both AsPC-1 and SK-OV-3. For example at 10 µM the irradiated 
unconjugated duramycin reduced cell survival to 48.7% in AsPC-1 and 60.6% in SK-OV-3. Indeed 
unconjugated duramycin reduced cell survival in a concentration dependent manner in all 4 cell lines. 
However this is to be expected due to the cytotoxic abilities of unconjugated duramycin at these 
concentrations as seen previously [15]. 
  
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Duramycin-porphyrin conjugates for PDT 
10 
 
4. Discussion 
Conjugation of tetrapyrroles to peptides can be chemically challenging due to the requirement of 
bringing the two moieties together regio-selectively whilst maintaining their separate functionalities 
[36].  
In this study conjugation occurred by the formation of a covalent amide bond between an N-
hydroxysuccinimide (NHS) ester of the porphyrin and the ε-amino group on the lysine residue at 
duramycin’s N-terminal. The conjugation of the porphyrin to duramycin at this chosen location should 
minimise interference with the PE binding site [3]. A number of biological molecules conjugated to 
porphyrin through lysine residues have been shown to retain their antimicrobial function [39-41]. The 
scFv antibody fragment LAG-3 when conjugated through its lysine residues to a porphyrin PS was shown 
to bind to the colorectal cancer cell line Caco-2 and effectively induce cell death following 15 J/cm2 light 
treatment [18]. In this study the duramycin-porphyrin conjugate was used to detect cell surface PE 
expression on the 4 cancer cell lines A2780, AsPC-1, MIA PaCa-2 and SK-OV-3 via flow cytometry. In this 
way the conjugate was tested to see whether the duramycin component’s ability to bind the 
ethanolamine head group of PE had been altered during conjugation. It was also assessed herein 
whether the porphyrin had retained its fluorescent properties. The conjugate detected PE expression on 
all 4 cell lines and was detected in a concentration dependent manner thus verifying the conjugates 
ability to bind its target and maintain detectable fluorescence. To further investigate whether the 
conjugate’s PE binding ability was affected by the conjugation procedure a competition assay was 
performed via flow cytometry. Unconjugated duramycin did not have the ability to outcompete the 
conjugate for binding of cell surface PE. The median PE fluorescence detected remained constant for 
MIA PaCa-2 cells over the 30 minute time course and was seen to slightly increase for A2780. 
We have previously reported that unconjugated duramycin has an effect on the FSC and SSC properties 
of cancer cell lines [15]. Duramycin has the ability to increase cell size (FSC) of AsPC-1 cells at >50 µM 
and increase cell granularity (SSC) of A2780, AsPC-1, MIA PaCa-2 and SK-OV-3 at >200 µM. Necrotic cell 
death is associated with swelling of the cell followed by rapid release of intracellular content and an 
increase in granularity which have been linked to an increase in FSC and SSC, respectively [42]. An 
increase in SSC was seen to correlate with increased granularity in prostate cancer cells (LNCaP and PC3) 
[43]. Cells with an increased SSC in the renal proximal tubular epithelial cell line LLC-PK1 were identified 
as apoptotic by flow cytometry and those with an increased FSC as necrotic [44]. Heightened SSC was 
also seen in early apoptotic cells where condensation of the cell nucleus and cytoplasm during cell 
shrinkage lead to enhanced light refraction [45]. However it is important to state that morphological and 
cell size changes measured via light scatter should be considered as supportive rather than as definitive 
evidence of cell death. We have previously shown via confocal imaging that duramycin treated AsPC-1 
cells lose cell membrane staining accompanied with an uptake of propidium iodide suggesting a loss in 
membrane integrity or cell death. An increase in cell size was also observed, which is indicative of cell 
swelling prior to cell death [15]. The duramycin-porphyrin conjugate also effected the FSC/ SSC 
properties of the ovarian and pancreatic cancer cell lines. FSC was increased in A2780 and MIA PaCa-2 
when treated with 1 mM conjugate and SSC increased in all 4 cell lines though AsPC-1 and MIA PaCa-2 at 
>250 µM and A2780 and SK-OV-3 at 1 mM. The similar effects on FSC and SSC produced by duramycin 
and duramycin-porphyrin conjugate could provide additional evidence of duramycin’s maintained 
functionality when conjugated to porphyrin. The higher concentration of conjugate required to exert 
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this effect on the cell lines compared to duramycin alone is beneficial to PDT where minimal non-specific 
damage is a desired characteristic of any PS [25]. 
A number of studies in the literature have investigated the effect of PDT on ovarian and pancreatic 
cancer in a variety of models including cell lines [46], 3D cell culture [47-49], transplanted mice [50, 51] 
and Phase I/II human trials [52, 53]. A benzoporphyrin derivative (BPD) at 0.25 µM was able to reduce 
cell viability and volume in the human ovarian carcinoma cell line OVCAR5 and penetrate well through 
OVCAR5 3D cell culture [47, 48]. In another study in which OVCAR5 cells were grown in a culture film a 
fibre optic delivery system was used where the PS (pheophorbide) and oxygen gas was delivered 
separately [49]. Good diffusion of the PS to cells beyond the reach of the probe tip was observed. Balb/C 
mice transplanted with the ovarian cancer cell line OVCAR3 where treated with an immunoconjugated 
PS and irradiated with in vivo results showing targeted treatment and minimal damage to the 
surrounding vasculature [50]. A pancreatic cell line panel showed the cancer cell line AsPC-1 was 
particularly sensitive to PDT. Treatment of this cell line with verteporfin at 250 nM with a light dose of 
10 J/cm2 was effective enough to induce complete cell death [46]. Verteporfin has been used 
successfully in a Phase I/II trial against advanced pancreatic cancer where it accumulated quickly in the 
target tissue, induced necrotic cell death and had a fast clearance via excretion in bile [53].  
In this study we used 2 ovarian and 2 pancreatic cancer cell lines to evaluate the cytotoxic extent of our 
newly developed PS, duramycin-porphyrin conjugate, taking advantage of duramycin’s specificity for cell 
surface expressed PE. The duramycin-porphyrin conjugate was able to reduce cell survival of all 4 cancer 
cell lines after irradiation with a light dose of 7.5 J/cm2 red light. The significant difference in cell survival 
between the non-irradiated and irradiated cells treated with the conjugate occurred at 2.5 µM for 
A2780, AsPC-1 and SK-OV-3. MIA PaCa-2 exhibited less sensitivity to the PDT light treatment and a 
significant drop in cell survival occurred only when cells were treated with 5 µM conjugate. Treatment 
with 10 µM conjugate was effective enough to reduce cell survival to <3.2% in A2780, AsPC-1 and SK-
OV-3. However cell survival in MIA PaCa-2 was only ever reduced to 36.3% at the highest concentration. 
Reduction in cell survival of MIA PaCa-2 in conjugate treated cells was not significantly different to 
unconjugated duramycin treated cells. The greater resistance to irradiation and the lack of increased 
cytotoxic effect of the conjugate over duramycin alone may suggest that MIA PaCa-2 cancer cells may 
not be a candidate for PDT using this PS. Out of the 2 pancreatic cancer cell lines used in this study MIA 
PaCa-2  is the less aggressive form. Samkoe et al. [51] discovered that aggressive, fast growing 
pancreatic cancer (AsPC-1) responded better to verteporfin PDT than the less aggressive cell line (PANC-
1) in transplanted mice. In their vascular occlusion experiments 40 J/cm light dose was enough to induce 
complete necrosis in the tumours of AsPC-1 transplanted mice but not in PANC-1. They concluded that 
this difference in reaction to light treatment between cell lines could depend on tumour aggressiveness 
and other inherent biophysical properties. It has been observed in human trials that these differences in 
response to light treatment are of clinical importance where light dose can raise different reactions even 
in patients with the same type of malignancy [20, 52]. 
The “capped” porphyrin control when irradiated reduced cell survival slightly in AsPC-1, SK-OV-3 and 
MIA PaCa-2 at 10 µM. In a recent study [29] this “capped” control porphyrin was used in PDT 
experiments against benign and malignant prostate cells to assess its cytotoxic potential. “Capped” 
porphyrin >8.75 µM was seen to induce necrosis and prevent colony forming in irradiated prostate cells. 
In the A2780 cancer cell line the capped porphyrin control produced similar levels of cytotoxicity as to 
that produced by the irradiated conjugate. An increased uptake and localisation of the “capped” 
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porphyrin could potentially explain this increased sensitivity. However DNA damage in the prostate cells 
(suggesting localisation occurred in the nucleus) was induced after 1 hour incubation with the porphyrin 
[29]. This movement into the cell and localisation of the “capped” control porphyrin is unlikely to have 
occurred in the A2780 cells in the relatively short incubation of 5 minutes used in this study. 
The differences in sensitivities to irradiation between cancer cell lines could potentially be explained by 
the cytoprotective mechanisms that cancer cells can employ to escape PDT induced cell death. 
Antioxidant molecules and detoxifying enzymes such as superoxide dismutase (SOD) present in cancer 
cells have been implicated in the protection against PDT effects [17]. Other cytoprotective mechanisms 
have been demonstrated to be induced by PDT itself including the i) initiation of stress-related 
transcription factors e.g. hypoxia inducible factor (HIF) and nuclear factor erythroid 2-related factor 2 
(NRF2), ii) increased heat shock protein (HSP) levels e.g. elevated HSP60 and HSP70 have been seen to 
be inversely correlated with PDT sensitivity and iii) inhibition of NF-ᴋB which can activate anti-apoptotic 
genes [17]. The literature reports at least some of these protective mechanisms are active in the ovarian 
and pancreatic cancer cell lines used in this study. An upregulation of HIF-1-α, an important factor in 
tumour metastasis and progression, was seen to accompany the hypoxic state of A2780 tumours [54] 
and has also been observed in hypoxia induced MIA PaCa-2 cells [55] and following oxidative stress-
induced ROS production in SK-OV-3 cells [56]. SK-OV-3 cells also have an upregulation of the antioxidant 
gene SOD2 [57] which could protect against harmful PDT effects. This ovarian cancer cell line has also 
been shown to have enhanced NF-ᴋB activity, when stimulated by ROS, which lead to the activation of 
anti-apoptotic genes [58]. NRF2 is the principal transcription factor of many antioxidant and 
detoxification genes and is overexpressed in A2780 [59], SK-OV-3 [60] and AsPC-1 cells [61, 62] and can 
be induced in the presence of ROS especially in pancreatic cancer [62]. HSPs can bind oxidatively 
damaged proteins and play a role in pro-survival pathways [17]. HSP70 is overexpressed in MIA PaCa-2 
cells [63] and is found in much higher quantities in tissue from patients with ovarian cancer than in 
normal ovarian tissue [64]. The effectiveness of PDT relies on an available and sustained oxygen supply 
to tissue, which may be reduced in hypoxic conditions [65]. A2780 xenografts in a murine model of 
ovarian cancer were found to be extremely hypoxic (2.0±0.7 mmHg) when compared to RIF-1 xenografts 
(7.8±1.4 mmHg); a typical hypoxic tumour model [54]. 
An important property of any good PS is a high intersystem crossing (ISC) yield i.e. a high possibility of 
conversion from the excited singlet state to the longer lived excited triplet state, from which energy 
transfer to ground state (triplet) oxygen occurs [20]. Tetrapyrroles, such as the porphyrin moiety used in 
this study, are very efficient at undergoing ISC [66]. The benefit of conjugating tetrapyrroles with 
peptides is that their small size allows for good tissue penetration and usually renders them non-
immunogenic [36]. An advantage of the type of porphyrin used in this study is that the conjugation 
procedure does not produce reactive intermediates or by-products [18, 35]. This porphyrin has 
previously been shown to exhibit antibacterial properties, be an efficient cytotoxic after 5 minutes 
irradiation and be stable against photodegradation [39]. The duramycin-porphyrin conjugate reported 
here is an effective PS for the targeted PDT treatment of cancer cells. With a relatively low (in vitro) 
cytotoxic concentration of 2.5 µM the conjugate offers benefits over unconjugated duramycin induced 
cell death. At these low concentrations duramycin does not cause necrosis but can reliably bind cell 
surface expressed PE [15]. Unconjugated duramycin has been shown to bind PE expressed on the 
tumour vasculature [1]. Through the possibility of targeted irradiance the duramycin-porphyrin 
conjugate could allow for specific death of the tumour and therefore reduce the risk of collateral 
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damage to surrounding normal tissue. Photodynamic effect usually occurs very close to the localisation 
of the PS [17] and when the PS’s binding site is the plasma membrane necrotic cell death can very 
rapidly follow irradiation [67]. As the duramycin-porphyrin conjugate binds to cancer cell membranes it 
is possible that cell death occurs via rapid necrosis which may reduce the risk of PDT-induced 
cytoprotective mechanisms. 
PDT is evidently an effective anti-cancer therapy though only a limited number of PS have been 
approved by the FDA and EU for use in the clinical setting [20, 26]. For PDT to be better utilised as a 
treatment strategy the development of PS that possess selectivity for binding sites overexpressed or 
enhanced on a wide range of cancer types is needed. In this proof of concept study we have shown that 
the PS duramycin-porphyrin conjugate retained good binding affinity for its target and, following 
irradiation, reduced cell survival of pancreatic and ovarian cancer cell lines in a concentration dependent 
manner. As we have previously shown, duramycin has the ability to bind to cell surface expressed PE on 
a range of cancer cell lines [15], and so we hypothesise that this PS could potentially be used against a 
number of different cancer types. Further work with duramycin-porphyrin conjugate in the in vivo 
environment could potentially confirm this conjugate as a promising new PS in the PDT treatment of 
cancer.
 
Conflict(s) of Interest 
The authors declare that they have no conflicts of interest with the contents of this article.  
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Duramycin-porphyrin conjugates for PDT 
14 
 
References 
1. Stafford, J.H. and P.E. Thorpe, Increased Exposure of Phosphatidylethanolamine on the Surface 
of Tumor Vascular Endothelium. Neoplasia, 2011. 13(4): p. 299-IN2. 
2. Zimmermann, N., S. Freund, A. Fredenhagen, and G. Jung, Solution structures of the lantibiotics 
duramycin B and C. European Journal of Biochemistry, 1993. 216(2): p. 419-428. 
3. Zhao, M., Lantibiotics as probes for phosphatidylethanolamine. Amino Acids, 2011. 41(5): p. 
1071-1079. 
4. Aoki, Y., T. Uenaka, J. Aoki, M. Umeda, and K. Inoue, A novel peptide probe for studying the 
transbilayer movement of phosphatidylethanolamine. Journal of biochemistry, 1994. 116(2): p. 
291-297. 
5. Hayashi, F., K. Nagashima, Y. Terui, Y. Kawamura, K. Matsumoto, and H. Itazaki, The Structure Of 
PA48009: The Revised Structure. The Journal of Antibiotics, 1990. 43(11): p. 1421-1430. 
6. Fadeel, B. and D. Xue, The ins and outs of phospholipid asymmetry in the plasma membrane: 
roles in health and disease. Crit Rev Biochem Mol Biol, 2009. 44(5): p. 264-77. 
7. van Meer, G., D.R. Voelker, and G.W. Feigenson, Membrane lipids: where they are and how they 
behave. Nat Rev Mol Cell Biol, 2008. 9(2): p. 112-24. 
8. Daleke, D.L., Phospholipid flippases. J Biol Chem, 2007. 282(2): p. 821-5. 
9. Sahu, S.K., S.N. Gummadi, N. Manoj, and G.K. Aradhyam, Phospholipid scramblases: an 
overview. Arch Biochem Biophys, 2007. 462(1): p. 103-14. 
10. Zwaal, R.F.A. and A.J. Schroit, Pathophysiologic Implications of Membrane Phospholipid 
Asymmetry in Blood Cells. Blood, 1997. 89(4): p. 1121-1132. 
11. Emoto, K., N. Toyama-Sorimachi, H. Karasuyama, K. Inoue, and M. Umeda, Exposure of 
Phosphatidylethanolamine on the Surface of Apoptotic Cells. Experimental Cell Research, 1997. 
232(2): p. 430-434. 
12. Zwaal, R.F.A., P. Comfurius, and E.M. Bevers, Lipid–protein interactions in blood coagulation. 
Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1998. 1376(3): p. 433-453. 
13. Falls, L.A., B. Furie, and B.C. Furie, Role of Phosphatidylethanolamine in Assembly and Function 
of the Factor IXa−Factor VIIIa Complex on Membrane Surfaces†. Biochemistry, 2000. 39(43): p. 
13216-13222. 
14. Yates, K.R., J. Welsh, N.O. Udegbunam, J. Greenman, A. Maraveyas, and L.A. Madden, 
Duramycin exhibits antiproliferative properties and induces apoptosis in tumour cells. Blood 
Coagul Fibrinolysis, 2012. 23(5): p. 396-401. 
15. Broughton, L.J., C. Crow, A. Maraveyas, and L.A. Madden, Duramycin-induced calcium release in 
cancer cells. Anti-Cancer Drugs, 2016. 27(3): p. 173-182. 
16. Larson, M.C., J.E. Woodliff, C.A. Hillery, T.J. Kearl, and M. Zhao, Phosphatidylethanolamine is 
externalized at the surface of microparticles. Biochimica et Biophysica Acta (BBA) - Molecular 
and Cell Biology of Lipids, 2012. 1821(12): p. 1501-1507. 
17. Agostinis, P., K. Berg, K.A. Cengel, T.H. Foster, A.W. Girotti, S.O. Gollnick, S.M. Hahn, M.R. 
Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. Nowis, J. Piette, B.C. Wilson, 
and J. Golab, Photodynamic therapy of cancer: an update. CA Cancer J Clin, 2011. 61(4): p. 250-
81. 
18. Staneloudi, C., K.A. Smith, R. Hudson, N. Malatesti, H. Savoie, R.W. Boyle, and J. Greenman, 
Development and characterization of novel photosensitizer : scFv conjugates for use in 
photodynamic therapy of cancer. Immunology, 2007. 120(4): p. 512-7. 
19. Korbelik, M., PDT-associated host response and its role in the therapy outcome. Lasers Surg Med, 
2006. 38(5): p. 500-8. 
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Duramycin-porphyrin conjugates for PDT 
15 
 
20. Zhu, T.C. and J.C. Finlay, The role of photodynamic therapy (PDT) physics. Medical Physics, 2008. 
35(7): p. 3127. 
21. Nestor, M.S., M.H. Gold, A.N. Kauvar, A.F. Taub, R.G. Geronemus, E.C. Ritvo, M.P. Goldman, D.J. 
Gilbert, D.F. Richey, T.S. Alster, R.R. Anderson, D.E. Bank, A. Carruthers, J. Carruthers, D.J. 
Goldberg, C.W. Hanke, N.J. Lowe, D.M. Pariser, D.S. Rigel, P. Robins, J.M. Spencer, and B.D. 
Zelickson, The use of photodynamic therapy in dermatology: results of a consensus conference. J 
Drugs Dermatol, 2006. 5(2): p. 140-54. 
22. Braathen, L.R., R.M. Szeimies, N. Basset-Seguin, R. Bissonnette, P. Foley, D. Pariser, R. Roelandts, 
A.M. Wennberg, C.A. Morton, and D. International Society for Photodynamic Therapy in, 
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international 
consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad 
Dermatol, 2007. 56(1): p. 125-43. 
23. Jerjes, W., T. Upile, S. Akram, and C. Hopper, The surgical palliation of advanced head and neck 
cancer using photodynamic therapy. Clin Oncol (R Coll Radiol), 2010. 22(9): p. 785-91. 
24. Wolfsen, H.C., Carpe luz--seize the light: endoprevention of esophageal adenocarcinoma when 
using photodynamic therapy with porfimer sodium. Gastrointest Endosc, 2005. 62(4): p. 499-
503. 
25. Nowis, D., M. Makowski, T. Stoklosa, M. Legat, T. Issat, and J. Golab, Direct tumor damage 
mechanisms of photodynamic therapy. Acta Biochim Pol, 2005. 52(2): p. 339-52. 
26. Baldea, I., R.M. Ion, D.E. Olteanu, I. Nenu, D. Tudor, and A.G. Filip, Photodynamic therapy of 
melanoma using new, synthetic porphyrins and phthalocyanines as photosensitisers - a 
comparative study. Clujul Med, 2015. 88(2): p. 175-80. 
27. Spikes, J.D., Porphyrins and related compounds as photodynamic sensitizers. Ann N Y Acad Sci, 
1975. 244: p. 496-508. 
28. Yang, X., P. Palasuberniam, D. Kraus, and B. Chen, Aminolevulinic Acid-Based Tumor Detection 
and Therapy: Molecular Mechanisms and Strategies for Enhancement. Int J Mol Sci, 2015. 
16(10): p. 25865-80. 
29. Frame, F.M., H. Savoie, F. Bryden, F. Giuntini, V.M. Mann, M.S. Simms, R.W. Boyle, and N.J. 
Maitland, Mechanisms of growth inhibition of primary prostate epithelial cells following gamma 
irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not 
apoptosis. Cancer Med, 2016. 5(1): p. 61-73. 
30. Vrouenraets, M.B., G.W. Visser, F.A. Stewart, M. Stigter, H. Oppelaar, P.E. Postmus, G.B. Snow, 
and G.A. van Dongen, Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody 
conjugates for photoimmunotherapy. Cancer Res, 1999. 59(7): p. 1505-13. 
31. Del Governatore, M., M.R. Hamblin, E.E. Piccinini, G. Ugolini, and T. Hasan, Targeted 
photodestruction of human colon cancer cells using charged 17.1A chlorin e6 
immunoconjugates. Br J Cancer, 2000. 82(1): p. 56-64. 
32. Hamblin, M.R. and E.L. Newman, Photosensitizer targeting in photodynamic therapy. II. 
Conjugates of haematoporphyrin with serum lipoproteins. J Photochem Photobiol B, 1994. 26(2): 
p. 147-57. 
33. Schmidt-Erfurth, U., H. Diddens, R. Birngruber, and T. Hasan, Photodynamic targeting of human 
retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer, 1997. 75(1): 
p. 54-61. 
34. Vega, D.L., P. Lodge, and J.L. Vivero-Escoto, Redox-Responsive Porphyrin-Based 
Polysilsesquioxane Nanoparticles for Photodynamic Therapy of Cancer Cells. Int J Mol Sci, 2016. 
17(1). 
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Duramycin-porphyrin conjugates for PDT 
16 
 
35. Sutton, J.M., O.J. Clarke, N. Fernandez, and R.W. Boyle, Porphyrin, chlorin, and bacteriochlorin 
isothiocyanates: useful reagents for the synthesis of photoactive bioconjugates. Bioconjug Chem, 
2002. 13(2): p. 249-63. 
36. Giuntini, F., C.M. Alonso, and R.W. Boyle, Synthetic approaches for the conjugation of porphyrins 
and related macrocycles to peptides and proteins. Photochem Photobiol Sci, 2011. 10(5): p. 759-
91. 
37. Li, Z., C.W. Wells, P.E. North, S. Kumar, C.B. Duris, J.A. McIntyre, and Z. Ming, 
Phosphatidylethanolamine at the luminal endothelial surface--implications for hemostasis and 
thrombotic autoimmunity. Clin Appl Thromb Hemost, 2011. 17(2): p. 158-63. 
38. Zhao, M., Z. Li, and S. Bugenhagen, 99mTc-labeled duramycin as a novel 
phosphatidylethanolamine-binding molecular probe. J Nucl Med, 2008. 49(8): p. 1345-52. 
39. Tome, J.P., M.G. Neves, A.C. Tome, J.A. Cavaleiro, M. Soncin, M. Magaraggia, S. Ferro, and G. 
Jori, Synthesis and antibacterial activity of new poly-S-lysine-porphyrin conjugates. J Med Chem, 
2004. 47(26): p. 6649-52. 
40. Soukos, N.S., L.A. Ximenez-Fyvie, M.R. Hamblin, S.S. Socransky, and T. Hasan, Targeted 
Antimicrobial Photochemotherapy. Antimicrobial Agents and Chemotherapy, 1998. 42(10): p. 
2595-2601. 
41. Polo, L., A. Segalla, G. Bertoloni, G. Jori, K. Schaffner, and E. Reddi, Polylysine-porphycene 
conjugates as efficient photosensitizers for the inactivation of microbial pathogens. J Photochem 
Photobiol B, 2000. 59(1-3): p. 152-8. 
42. Dive, C., C.D. Gregory, D.J. Phipps, D.L. Evans, A.E. Milner, and A.H. Wyllie, Analysis and 
discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow 
cytometry. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1992. 1133(3): p. 275-
285. 
43. Haynes, M.K., J.J. Strouse, A. Waller, A. Leitao, R.F. Curpan, C. Bologa, T.I. Oprea, E.R. Prossnitz, 
B.S. Edwards, L.A. Sklar, and T.A. Thompson, Detection of intracellular granularity induction in 
prostate cancer cell lines by small molecules using the HyperCyt high-throughput flow cytometry 
system. J Biomol Screen, 2009. 14(6): p. 596-609. 
44. Healy, E., M. Dempsey, C. Lally, and M.P. Ryan, Apoptosis and necrosis: mechanisms of cell death 
induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int, 1998. 54(6): p. 1955-
66. 
45. Wlodkowic, D., W. Telford, J. Skommer, and Z. Darzynkiewicz, Apoptosis and beyond: cytometry 
in studies of programmed cell death. Methods Cell Biol, 2011. 103: p. 55-98. 
46. Celli, J.P., N. Solban, A. Liang, S.P. Pereira, and T. Hasan, Verteporfin-based photodynamic 
therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers 
Surg Med, 2011. 43(7): p. 565-74. 
47. Rizvi, I., S. Anbil, N. Alagic, J. Celli, L.Z. Zheng, A. Palanisami, M.D. Glidden, B.W. Pogue, and T. 
Hasan, PDT dose parameters impact tumoricidal durability and cell death pathways in a 3D 
ovarian cancer model. Photochem Photobiol, 2013. 89(4): p. 942-52. 
48. Anbil, S., I. Rizvi, J.P. Celli, N. Alagic, B.W. Pogue, and T. Hasan, Impact of treatment response 
metrics on photodynamic therapy planning and outcomes in a three-dimensional model of 
ovarian cancer. J Biomed Opt, 2013. 18(9): p. 098004. 
49. Bartusik, D., D. Aebisher, A. Ghogare, G. Ghosh, I. Abramova, T. Hasan, and A. Greer, A fiberoptic 
(photodynamic therapy type) device with a photosensitizer and singlet oxygen delivery probe tip 
for ovarian cancer cell killing. Photochem Photobiol, 2013. 89(4): p. 936-41. 
50. Goff, B.A., J. Blake, M.P. Bamberg, and T. Hasan, Treatment of ovarian cancer with 
photodynamic therapy and immunoconjugates in a murine ovarian cancer model. British Journal 
of Cancer, 1996. 74(8): p. 1194-1198. 
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Duramycin-porphyrin conjugates for PDT 
17 
 
51. Samkoe, K.S., A. Chen, I. Rizvi, J.A. O'Hara, P.J. Hoopes, S.P. Pereira, T. Hasan, and B.W. Pogue, 
Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft 
models. Int J Radiat Oncol Biol Phys, 2010. 76(1): p. 251-9. 
52. Bown, S.G., A.Z. Rogowska, D.E. Whitelaw, W.R. Lees, L.B. Lovat, P. Ripley, L. Jones, P. Wyld, A. 
Gillams, and A.W.R. Hatfield, Photodynamic therapy for cancer of the pancreas. Gut, 2002. 50(4): 
p. 549-557. 
53. Huggett, M.T., M. Jermyn, A. Gillams, R. Illing, S. Mosse, M. Novelli, E. Kent, S.G. Bown, T. Hasan, 
B.W. Pogue, and S.P. Pereira, Phase I/II study of verteporfin photodynamic therapy in locally 
advanced pancreatic cancer. Br J Cancer, 2014. 110(7): p. 1698-704. 
54. Selvendiran, K., A. Bratasz, M.L. Kuppusamy, M.F. Tazi, B.K. Rivera, and P. Kuppusamy, Hypoxia 
induces chemoresistance in ovarian cancer cells by activation of signal transducer and activator 
of transcription 3. Int J Cancer, 2009. 125(9): p. 2198-204. 
55. Sibenaller, Z.A., J.L. Welsh, C. Du, J.R. Witmer, H.E. Schrock, J. Du, G.R. Buettner, P.C. Goswami, 
J.A. Cieslak, 3rd, and J.J. Cullen, Extracellular superoxide dismutase suppresses hypoxia-inducible 
factor-1alpha in pancreatic cancer. Free Radic Biol Med, 2014. 69: p. 357-66. 
56. Wang, Y., J. Ma, H. Shen, C. Wang, Y. Sun, S.B. Howell, and X. Lin, Reactive oxygen species 
promote ovarian cancer progression via the HIF-1alpha/LOX/E-cadherin pathway. Oncol Rep, 
2014. 32(5): p. 2150-8. 
57. Wang, Y., L. Dong, H. Cui, D.H. Shen, Y. Wang, X.H. Chang, T.Y. Fu, X. Ye, and Y.Y. Yao, Up-
regulation of mitochondrial antioxidation signals in ovarian cancer cells with aggressive biologic 
behavior. J Zhejiang Univ Sci B, 2011. 12(5): p. 346-56. 
58. Saunders, J.A., L.C. Rogers, C. Klomsiri, L.B. Poole, and L.W. Daniel, Reactive oxygen species 
mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med, 
2010. 49(12): p. 2058-67. 
59. Bao, L.J., M.C. Jaramillo, Z.B. Zhang, Y.X. Zheng, M. Yao, D.D. Zhang, and X.F. Yi, Nrf2 induces 
cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol, 
2014. 7(4): p. 1502-13. 
60. Cho, J.M., S. Manandhar, H.R. Lee, H.M. Park, and M.K. Kwak, Role of the Nrf2-antioxidant 
system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. 
Cancer Lett, 2008. 260(1-2): p. 96-108. 
61. Hong, Y.B., H.J. Kang, S.Y. Kwon, H.J. Kim, K.Y. Kwon, C.H. Cho, J.M. Lee, B.V. Kallakury, and I. 
Bae, Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer 
cells. Pancreas, 2010. 39(4): p. 463-72. 
62. Yi, Y.W. and S. Oh, Comparative analysis of NRF2-responsive gene expression in AcPC-1 
pancreatic cancer cell line. Genes Genomics, 2015. 37: p. 97-109. 
63. Walsh, N., A. Larkin, N. Swan, K. Conlon, P. Dowling, R. McDermott, and M. Clynes, RNAi 
knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down 
regulation. Cancer Lett, 2011. 306(2): p. 180-9. 
64. Kang, H.J., H.S. Moon, and H.W. Chung, The expression of FAS-associated factor 1 and heat shock 
protein 70 in ovarian cancer. Obstet Gynecol Sci, 2014. 57(4): p. 281-90. 
65. Golab, J., D. Olszewska, P. Mroz, K. Kozar, R. Kaminski, A. Jalili, and M. Jakobisiak, Erythropoietin 
restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-
induced anemia. Clin Cancer Res, 2002. 8(5): p. 1265-70. 
66. Josefsen, L.B. and R.W. Boyle, Photodynamic therapy and the development of metal-based 
photosensitisers. Met Based Drugs, 2008. 2008: p. 276109. 
67. Kessel, D. and R.D. Poretz, Sites of photodamage induced by photodynamic therapy with a 
chlorin e6 triacetoxymethyl ester (CAME). Photochem Photobiol, 2000. 71(1): p. 94-6. 
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Duramycin-porphyrin conjugates for PDT 
18 
 
 
Artwork with Captions 
 
 
Figure 1: Structure of duramycin-porphyrin conjugate. A covalent amide bond was formed through the 
reaction with the NHS ester of the porphyrin 5-[4-(N-succinimidyloxycarbonyl)phenyl]-10,15,20-tris(4-
methylpyridinium) porphyrin trichloride and the ε-amino group of the lysine residue at duramycin’s N-
terminal in the organic solvent DMSO. 
1.5 column fitting image 
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Figure 2: Detection of cell surface PE on ovarian and pancreatic cancer cell lines using duramycin-
porphyrin conjugate. i) Log10 median PE fluorescence (FL-4 flow cytometer channel, 635 nm laser) was 
used to express detected levels of PE. The conjugate was able to detect PE on the cell surface of all 4 
cancer cell lines, A2780, AsPC-1, MIA PaCa-2 and SK-OV-3, in a concentration dependent manner. Error 
bars show standard deviation of 2 replicates. ii) Flow cytometry histograms showing detectable shift in 
fluorescence on a) A2780, b) AsPC-1, c) MIA PaCa-2 and d) SK-OV-3 cells (purple) using 0.1 µM (green) 
and 10 µM (pink) duramycin-porphyrin conjugate. 
1 column fitting image 
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Figure 3: Competitive binding for PE between pre-bound duramycin-porphyrin conjugate and 
unconjugated duramycin. The unconjugated duramycin was unable to compete against the conjugate 
for cell surface PE on the cancer cell lines A2780 and MIA PaCa-2. The median PE fluorescence of MIA 
PaCa-2 remained constant, within standard deviation, at each interval across the 30 minute time course. 
However the median PE fluorescence of A2780 increased slightly over time. Error bars show standard 
deviation of 2 replicates. 
1.5 column fitting image 
 
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Duramycin-porphyrin conjugates for PDT 
21 
 
 
Figure 4: The effect of duramycin-porphyrin conjugate on the forward scatter and side scatter 
properties of ovarian and pancreatic cancer cell lines. The effect on FSC of a) unconjugated duramycin 
and b) duramycin-porphyrin conjugate and the effect on SSC of c) unconjugated duramycin and d) 
duramycin-porphyrin conjugate. Unconjugated duramycin has the ability to increase FSC (cell size) of 
AsPC-1 cells at >50 µM and increase SSC (cell granularity) of A2780, AsPC-1, MIA PaCa-2 and SK-OV-3 at 
>200 µM. Duramycin-porphyrin conjugate slightly increased FSC of A2780 and MIA PaCa-2 at 1 mM. SSC 
was increased in A2780 and SK-OV-3 when treated with 1mM conjugate and AsPC-1 and MIA PaCa-2 
when treated with >250 µM conjugate. Error bars show standard deviation of 2 replicates. 
2 column fitting image 
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Figure 5: PDT Treatment of ovarian and pancreatic cancer cell lines. The irradiated duramycin-
porphyrin conjugate at concentrations >2.5 µM significantly reduced cell survival of AsPC-1, A2780 and 
SK-OV-3 cells when compared to the non-irradiated conjugate. The irradiated conjugate >5 µM 
significantly reduced cell survival of MIA PaCa-2 cells when compared to the non-irradiated conjugate. a) 
The unconjugated duramycin caused a slight reduction in cell survival of A2780 cells at concentrations 
>5 µM. The irradiated capped porphyrin treated cells showed similar levels of cytotoxicity as the 
irradiated conjugate treated cells at concentrations >5 µM. b) The irradiated capped porphyrin reduced 
cell survival of MIA PaCa-2 cells slightly at the highest concentration of 10 µM. Reduction in cell survival 
in conjugate treated cells was not significantly different to unconjugated duramycin treated cells. c) and 
d) Both AsPC-1 and SK-OV-3 showed dark toxicity at concentrations with non-irradiated conjugate >5 
µM. The irradiated capped porphyrin control slightly reduced cell survival at 10 µM. Unconjugated 
duramycin showed cytotoxic effect in a concentration dependent manner. Error bars show standard 
deviation of 3 independent experiments with 4 repetitions each. 
2 column fitting image 
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Supplementary Data 
Supplementary Figure S-1: Semi-preparative HPLC of duramycin-porphyrin conjugate. Duramycin-
porphyrin conjugate was isolated by HPLC at Rt = 6.20 minutes with the additional collection of 
unreacted porphyrin at Rt = 7.01 and duramycin at Rt = 7.32 minutes (upper trace). The conjugate was 
purified by HPLC and collected at Rt = 6.20 minutes (lower trace). The break in the trace line on the 
lower trace represents the void time in which the solvent front eluted (as seen on upper trace). The 
small peak at Rt = 7.96 is a discrepancy within the instrument rather than the detection of another 
compound. 
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Supplementary Figure S-2: Electron ionising mass spectrometry of duramycin-porphyrin conjugate. 
The peak for the conjugate was found to be ESI-MS (+): 675.66 [(M+4H+)/4]4+ where the expected was 
675.67. Conjugate retention time; Rt = 7.34 minutes. The peaks at <300.00 were unidentified but were 
presumed to be a discrepancy within the machine most likely due to an impurity within the mass 
spectrometer. 
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